CV Therapeutics Feels the Pain

Shares in the drugmaker plummeted Wednesday after a clinical trial of its treatment for angina showed mixed results

CV Therapeutics' (CVTX) main drug, Ranexa, can only be used as a last-ditch treatment for coronary problems because of concerns that it might cause irregular heartbeats. So when the drug-maker on March 6 announced mixed results from a trial designed to evaluate Ranexa's safety and efficacy, investors sold the stock the next day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.